Dachau, Bavaria, Germany
- Leading the identification of novel targets and the hit-to-lead optimization of DNA origami-based T cell engagers - Expanding Plectonic’s technology platform
- Scientific and team leader in early immunotherapy R&D, with a strategic focus on indication and target selection, and technological platform expansion
- Leading and coordinating four ongoing projects in the field of cell therapies against solid cancers and hematological malignancies - Managing several collaboration projects in oncology and immune-oncology as part of external industry and academic partnerships
- Development of mutation-specific chimeric antigen receptor modified T cells as precision cell therapy for high-risk chronic lymphocytic leukemia - Development of a modular therapeutic platform consisting of engineered T cells and bispecific antibodies to target multiple tumor antigens
Research in Immune Biology: Antibody development
PCR and ligation of the limonene hydroxylase - Transformation of E. coli and expression - Purification with Ni2+-affinity- and size-exclusion-chromatography - Testing of the catalytic activity by performing an absorption kinetics measurement and by LC- und GC-MS